Biotechnology
Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapy
EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced today the recent exercise of Onward Therapeutics' second of three instalments of equity investment in Emercell. With this investment, On...
2022-06-20 12:00
1929
2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines
TAIPEI, Taiwan , June 18, 2022 /PRNewswire/ -- After the 2014 and 2016 winners for the Tang Prize in Biopharmaceutical Sciences were crowned the Nobel Prize in 2018 and 2020 respectively, this category has continued to garner much attention worldwide. After much waiting, names of the latest winne...
2022-06-19 10:30
3096
2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines
TAIPEI, Taiwan, June 18, 2022 /PRNewswire/ -- After the 2014 and 2016 winners for the Tang Prize in Biopharmaceutical Sciences were crowned the Nobel Prize in 2018 and 2020 respectively, this category has continued to garner much attention worldwide. After much waiting, names of the latest winner...
2022-06-19 10:30
3186
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatmen...
2022-06-17 20:00
3846
Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis
HONG KONG, June 17, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK"...
2022-06-17 04:20
3110
Insilico Medicine appoints Dr. Feng Ren as co-CEO
Dr. Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is named co-CEO of Insilico Medicine Highlights: * Insilico Medicine is a global, end-to-end, fully-integrated AI-powered biotechnology company with three business models: AI platform, collaboration, and ...
2022-06-16 21:03
3819
Global Cord Blood Corporation Announces Purported EGM Is Not Validly Convened
HONG KONG, June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, noticed that onJune 3, 2022 Blue Ocean Structure Inv...
2022-06-16 20:30
4507
Global Pharmaceutical Market Drives Innovative Digitalization to Accelerate Drug Discovery
According to Frost & Sullivan, digitalization across the pharmaceutical value chain will improve the industry´s efficiency. SAN ANTONIO, June 16, 2022 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global Pharmaceuticals Outlook, finds that the accelerated drug development timelines are driv...
2022-06-16 15:12
2067
Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
GAITHERSBURG, Md. and SUZHOU, China, June 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the peer-reviewed publication of Phase IIa clinical study results of its lead th...
2022-06-16 13:01
2492
GILEAD SCIENCES NEW DATA HIGHLIGHTS PEOPLE LIVING WITH HIV WHO ARE VIRALLY SUPPRESSED EXPERIENCE SIMILAR HEALTH-RELATED QUALITY OF LIFE AS GENERAL POPULATION
– Data in Taiwan Shows That Antiretroviral Therapies Have Helped Transform HIV Into a Chronic Condition and Bring Positive Change in the Outlook for People Living with HIV– SINGAPORE, June 16, 2022 /PRNewswire/ -- Gilead Sciences, Inc. today announced results from an online survey that assessed ...
2022-06-16 11:15
2453
WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies
PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 15, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based inSt. Louis and San Diego, today announced a ...
2022-06-16 08:00
1935
Novotech and Medidata expand partnership to continue advancements in clinical research
Leading Asia-Pacific biotech specialist CRO Novotech and Medidata renew partnership, further expanding services to Novotech clients in APAC and the US SINGAPORE, June 16, 2022 /PRNewswire/ -- Medidata, a Dassault Systèmes company, today announced its renewed, expanded partnership with Novotech, a...
2022-06-16 08:00
2634
SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting
BOSTON and LAUSANNE, Switzerland, June 16, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), is pleased to announce the Annual General Meeting ("the Meeting") was held at the Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD,Switzerland, earlier today at 2:00 p....
2022-06-16 00:15
2161
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner Morpho...
2022-06-15 22:37
2611
AnchorDx's Non-invasive Lung Cancer Early Diagnosis Product, PulmoSeek, Completes EU CE Marking Requirements
The company obtained a European Access Permit for in-vitro diagnostics devices (IVDD) authorized by the Netherlands CIBG of Ministry of Health, Welfare and Sport. GUANGZHOU, China, June 15, 2022 /PRNewswire/ -- PulmoSeekTM Lung Cancer Early Detection Assay, the non-invasive blood-based cfDNA met...
2022-06-15 21:00
2262
Burning Rock Presents Latest Clinical Data from THUNDER Study at 2022 ASCO Annual Meeting
SHANGHAI, June 15, 2022 /PRNewswire/ -- Burning Rock (NASDAQ:BNR) presented the final results from the multi-center case-control THUNDER study (THe UNintrusive Detection of EaRly-stage cancer, NCT04820868) in a poster entitled "Unintrusive multi-cancer detection by circulating cell-free DNA methy...
2022-06-15 20:01
2095
Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development
VANCOUVER, BC, June 15, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils deLyon in France ("HCL") has surgically excised the first ovarian cancer tumors from cancer ...
2022-06-15 20:00
4120
Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product
* Lonza will provide clinical drug product manufacturing for W0180, an oncology drug candidate discovered byPierre Fabre targeting solid tumors, from its fill and finish facility in Stein,Switzerland * Pierre Fabre will leverage Lonza's drug product expertise and fill and finish capabilities ...
2022-06-15 14:30
2103
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, June. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of ...
2022-06-14 20:00
1365
Zhimeng Biopharma will report positive phase 1b trial results on its HBV capsid inhibitor ZM-H1505R in the upcoming International Liver Congress
SHANGHAI, June 14, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma announces that it will report the positive results obtained from a phase1b study on its HBV capsid inhibitor ZM-H1505R in the International Liver Congress inJune 22-26, 2022 (the EASL meeting). The recently completed phase 1b stu...
2022-06-14 20:00
1189
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 295 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 292 media titles]
2024-11-26 13:00Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9289
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7761
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
6856
